This just came into my email inbox:
“Dong-A PharmTech Co., Ltd. [a Korean drug company] announced today that it has completed a 340 patient phase 2b ‘at-home’ clinical study for udenafil, its new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED).”
Does anyone else find this amusing?







![6 Digital Tools at the Center of Healthcare Digitalization [INFOGRAPHIC]](http://ec2-54-175-84-28.compute-1.amazonaws.com/pharma-mkting.com/wp-content/uploads/2021/04/6DigitalTools_600px-100x70.jpg)




